NLS Pharmaceutics (NLSP) Stock Price, News & Analysis

Company Overview

NLS Pharmaceutics (NASDAQ: NLSP) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.

The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia. Its lead candidate has advanced into mid-stage clinical trials, where the company is evaluating safety, tolerability and efficacy in patients experiencing severe disruptions in their sleep-wake patterns. Preclinical programs are also exploring additional indications in related neurophysiological and metabolic conditions.

Founded in 2015, NLS Pharmaceutics has built a research platform that integrates advanced pharmacokinetic modeling with circadian biology to enhance therapeutic outcomes. The company collaborates with academic institutions and sleep-medicine centers in North America and Europe to support patient recruitment and biomarker development. Through these partnerships, NLS Pharmaceutics aims to accelerate proof-of-concept studies and bring innovative treatments to market more efficiently.

NLS Pharmaceutics is led by an executive team with extensive experience in drug discovery, clinical development and regulatory affairs. The company’s strategy centers on addressing underserved patient populations and leveraging its circadian platform to expand into new therapeutic areas. By focusing on precise modulation of biological rhythms, NLS Pharmaceutics seeks to deliver differentiated therapies that improve quality of life for patients with chronic sleep and circadian disorders.

Key Stats

• Today's Range: $1.64 to $1.70
• 50-Day Range: $1.63 to $2.79
• 52-Week Range: $1.30 to $5.40
• Volume: 19,272 shs
• Average Volume: 949,788 shs
• Market Capitalization: $5.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

NLSP Stock Analysis - Frequently Asked Questions

How have NLSP shares performed this year?

NLS Pharmaceutics' stock was trading at $2.11 on January 1st, 2025. Since then, NLSP stock has decreased by 21.3% and is now trading at $1.66.

When did NLS Pharmaceutics IPO?

NLS Pharmaceutics (NLSP) raised $20 million in an initial public offering on Friday, January 29th 2021. The company issued 3,600,000 shares at $5.00-$6.00 per share. Maxim Group LLC acted as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager.

How do I buy shares of NLS Pharmaceutics?

Shares of NLSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NLS Pharmaceutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NLS Pharmaceutics investors own include Intel (INTC), Meta Platforms (META), Immunic (IMUX), Seres Therapeutics (MCRB), NVIDIA (NVDA), Tesla (TSLA).

Company Calendar

• Today: 10/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NLSP
• CIK: 1783036
• Web: www.nlspharma.com
• Phone: 41-44-512-2150
• Fax: 41-41-618-8009
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.77
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.37) per share
• Price / Book: -4.46

Miscellaneous

• Outstanding Shares: 3,600,000
• Free Float: 3,008,000
• Market Cap: $5.94 million
• Optionable: Not Optionable
• Beta: 0.14